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ABSTRACT 
Prostasin is expressed in normal prostate epithelial cells but down-regulated in prostate 
cancers, while prostasin re-expression in invasive prostate cancer cells reduced invasion.  We 
examined prostasin expression and function in benign prostatic hyperplasia (BPH). We 
evaluated prostasin expression in 12 BPH specimens by immunohistochemistry, and 
evaluated the impact of prostasin silencing by siRNA on the expression of the inducible nitric 
oxide synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), and cyclin D1, as well 
as on cell proliferation and invasion, using the BPH-1 human prostate epithelial cell line 
model.  Prostasin expression was localized in the glands of BPH tissues by 
immunohistochemistry, in either the tall columnar-shaped or the flattened epithelial cells.  
We silenced prostasin expression by >50% at both the mRNA and protein levels using 
siRNA in the BPH-1 human prostate epithelial cell line, and this silencing of prostasin 
expression was associated with an induction of iNOS and ICAM-1 expression and a down-
regulation of cyclin D1 expression.  The protein expression of EGFR, a putative prostasin 
substrate, was not affected by prostasin silencing in this cell line.  The prostasin-silenced cells 
displayed a reduced cell proliferation rate and reduced invasiveness, cell behaviors regulated 
by cyclin D1, iNOS, and ICAM-1 in the BPH-1 cells.  We believe that this down-regulation 
of cyclin D1 is due to prostasin’s augmentative effect on iNOS. We also believe that the 
decrease in cell motility is due to an increase in iNOS and ICAM-1 as well as a decrease in 
cyclin D1, since all of these molecules can play a role in cell motility.  In conclusion, 
Prostasin is somehow involved in the regulation of inflammatory gene expression (iNOS and 
ICAM-1) in prostate epithelial cells, as well as cyclin D1 expression, cell proliferation and 
invasion, involving molecular mechanisms different than those in the prostate cancer 
cells.  These studies suggest that prostasin is a player in the glandular components of 
benign prostatic hyperplasia. 
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INTRODUCTION 
 
The prostate is a male-specific sex accessory organ located at the base of the 
bladder [1]. The prostate does not have a clearly defined physiological function [1].  It is 
thought that the prostate produces somewhere around 20-30% of the ejaculate fluid.  It 
may also produce the proteolytic enzymes, acid phosphatase, prostate-specific antigen, 
and zinc that function in sperm motility and penetration, but these molecules are not 
essential for fertility [1].  The prostate has three anatomically distinct zones as described 
by McNeal, the central zone, the peripheral zone, and the transitional zone [1].  The 
transition zone surrounds the prostatic urethra and comprises 5% of the glandular tissue 
[1]. The next region is the central zone.  The central zone surrounds the ejaculatory ducts 
[1].  Another region is called the peripheral zone [1].  It was historically thought that 
BPH only arises from the transition zone, however, new evidence is showing that the 
volume of the central/peripheral zone increases from the normal volume of 30cm3   [2].  
Since it is rare to see BPH nodules arising from the central/peripheral zone, it is thought 
that the nodules developing in the transition zone are protruding into the 
peripheral/central zone and causing it to increase in volume during BPH progression [2].  
A fibromuscular stroma surrounds the zones of the prostate that serves as the bed, or non-
functional framework of the prostate [1]. 
Prostate, the namesake of the glycosylphosphatidylinositol (GPI)-anchored 
extracellular serine protease prostasin/prss8/CAP-1, is affected by two major diseases, 
prostate cancer and benign prostatic hyperplasia (BPH). Benign prostatic hyperplasia is a 
very common condition among men, especially older men [3].  Age and family history 
are the most common risk factors [1].  Eighty-four percent of men over the age of 70 are 
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living with this condition [4].   BPH is essentially an enlarged prostate that causes LUTS, 
lower urinary tract symptoms.  This can include BOO (bladder outlet obstruction), weak 
stream, hesitancy, frequent urination, and acute urinary retention [5]. At the histological 
level BPH is hyperplasia of the stromal and glandular components of the prostate [5]. 
When the prostate enlarges, instead of pushing outward into the body cavity, it actually 
expands inward and cuts off the flow of urine through the urethra [6]. 
  It is the current opinion in the field that there are four possible causes of BPH.  
The first is hormone-mediated.  Steroid hormones play a significant role in the growth 
and function of the normal prostate as well as the development of BPH [7].  Intraprostatic 
estradiol levels increase in men with age along with prostate volume [7].  Later in life 
men start to have more estrogen than androgen [7].  This is due to the increase in 
aromatase, which aromatizes androgens into estrogen [7]. It is thought that this increase 
in the ratio of estrogen to testosterone could be the reason for the enlarged prostate [7]..  
Another theory is the stem cell theory, which postulates the development of BPH through 
an increase in the number of stem cells or through an abnormal increase in clonal 
expansion of amplifying or transit cells [8].  There is a third theory called “embryonic 
reawakening” [9].  This is the idea that ontogenic processes occur later in life and result 
in the formation of BPH nodules [9].  In 1937 it was proposed that inflammation of the 
prostate was the cause of BPH [10].  Since then these other theories have taken off as the 
accepted cause of BPH [10].  However, there is now a reversion back to the original idea 
that BPH is an inflammatory disease[10].   
 Currently there are minimally invasive therapies available for BPH, including 
microwave thermotherapy, water-induced thermotherapy, interstitial device-based 
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therapy, transurethral needle ablation, and transurethral resection of the prostate [11]. 
There are three classes of drug treatment which include 5 alpha reductase inhibitors, 
alpha-blockers, and anti-inflammatories.  Dutasteride (Avodart) and Finasteride (Proscar) 
are 5-alpha-reductase inhibitors, and drugs such as Tamulosin are all alpha-blockers.  The 
5-alpha-reductase inhibitors work to inhibit the production of the hormone 
dihydrotestosterone (DHT), a hormone that may be responsible for prostate enlargement 
[12]. A decrease in DHT can result in a promotion of prostate involution and a decrease 
in angiogenesis [12].  Alpha-blockers work on peripheral arteries and veins to inhibit 
vasodilation and smooth muscle contraction, relieving some of the symptoms of BPH 
[13].   Anti-inflammatories work to decrease inflammation that is thought to cause BPH. 
Prostasin is a GPI-anchored serine protease[14]. The expression and functional 
role of prostasin in the prostate with regard to prostate cancer have been extensively 
studied.   For BPH, however, the information on prostasin expression and function is 
lacking.     Prostasin is expressed abundantly in normal prostate epithelial cells but is 
down-regulated in high-grade prostate cancers or those associated with the hormone-
refractory phenotype, due to promoter DNA hypermethylation and increased expression 
of transcription repressors [15-18].  Prostasin re-expression in highly invasive human 
prostate cancer cell lines reduced invasiveness possibly as a result of epidermal growth 
factor receptor (EGFR) signal modulation via protease-dependent and independent 
mechanisms [19,20].  Currently the only well known functions of prostasin are its 
activation of the epithelial sodium channel γ-subunit, its maintenance of epidermal 
integrity, and its attenuation of inflammation-induced gene expression [21].   
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We examined pathologically confirmed BPH tissues presenting both stromal and 
glandular hyperplasia for prostasin expression by immunohistochemistry, and localized 
prostasin protein expression in two distinct types of glandular epithelial cells.  We also 
demonstrated prostasin expression in an immortalized but non-transformed human 
prostate epithelial cell line, the BPH-1 cell line [21].  We investigated prostasin’s 
functional role in the BPH-1 cell line by silencing prostasin expression using an siRNA.  
In association with prostasin silencing, iNOS, ICAM-1/CD54 expression was induced at 
the mRNA and protein levels, while the expression of cyclin D1 at the mRNA and the 
protein levels was reduced.  Prostasin-silenced BPH-1 cells were shown to proliferate at a 
lower rate and were less invasive.   
.      
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HYPOTHESIS 
  
Prostasin is known to be required for terminal epithelial differentiation [22].  It also 
includes data from a previous paper that prostasin’s down-regulation could be due to 
inflammation [23].  I hypothesize that prostasin silencing in the BPH-1 cell line will 
change the expression levels of iNOS, ICAM-1, and Cyclin D1, therefore changing the 
proliferation rate and invasiveness of the cell line.   
 
 5
MATERIALS AND METHODS 
 
Tissue preparation and immunohistochemistry: 
Parraffin-embedded prostate tissues from patients undergoing transurethral 
resection of the prostate (TURP) for BPH were obtained from Florida Hospital in 
Orlando with informed consent and institutional approval.  Twelve specimens with 
pathologically confirmed presentation of BPH were used for this study.  The procedures 
for immunohistochemistry were essentially as described before [15].  Sections 4μm thick 
were deparaffinized, rehydrated, and subjected to antigen retrieval in citrate acid buffer 
(pH 6.0).  The prostate sections were treated with 3% H202 in methanol followed by 
blocking in 5% goat serum in 1X PBS (pH 7.2).  Then sections were then incubated with 
a rabbit anti-human prostasin polyclonal antibody [24] in the blocking buffer at 4ºC 
overnight.  Other primary antibodies used include: rabbit anti-human androgen receptor 
antibody (1:50), rabbit anti-human cMet antibody (1:50), rabbit anti-human PSA 
antibody (1:200).  The sections were washed with 1X PBS for 3 times at 5 minutes each 
following the primary antibody incubation; before incubation with either a goat anti-
rabbit IgG serum (Vector Laboratories, Burlingame, CA, 1:100) or a goat anti-mouse IgG 
serum(Vector Laboratories, Burlingame, CA, 1:100)   The sections were then washed 
with 1X PBS for 3 times at 5 minutes each.  Then they were incubated with PAP (goat or 
mouse) (1:200) in 5% goat serum for one hour.  The sections were then washed again in 
1X PBS for 3 times at 5 minutes each.  The color reaction was performed by incubation 
the sections with DAB (3,3’-diaminobenzidinetetrahydrochloride) solution (0.5 mg/ml in 
0.03% H2O2)  for 15 minutes.  The sections were counterstained with hematoxylin and 
photographed.    
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 Cell Culture: 
BPH-1, an immortalized but non-transformed benign prostatic hyperplasia cell 
line was kindly provided by Dr. Simon Hayward of the Vanderbilt University Medical 
Center (Nashville, TN), and was cultured in RPMI-1640 supplemented with 5% fetal 
bovine serum (FBS) in a humidified incubator at 37ºC with 5% CO2 and 95% air.  
Passaging was performed as described [25].      
 
 siRNA T ransfection of BPH-1 cell line: 
The prostasin-specific short interfering RNA (siRNA) and a randomized control 
siRNA were described previously (Tong et al., 2004) and were synthesized by Integrated 
DNA Technologies (Coralville, IA).  BPH-1 cells were seeded in a 6-well plate at 3x105 
cells per well and were transfected with 125 picomoles of siRNA per well using 
Lipofectamine-2000 (Invitrogen, Carlsbad, CA).   The siRNA and Lipofectamine were 
allowed to incubate together for 15 minutes before being in contact with the cells.  After 
15 minutes, the solution was then added to each well containing 0.8ml of fresh media. 
Five hours after transfection, the cells were given fresh media.  Forty-eight hours after 
transfection, the cells were collected for RNA isolation, lysed in RIPA buffer for western 
blot analysis, or trypsinized for proliferation and invasion assays.  
  
Western Blot Analysis:  
The procedures for western blot analysis were as described previously [15].  
Briefly, cells were washed two times in 1X PBS then lysed in RIPA buffer at 4ºC for 15 
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minutes (RIPA buffer = 20mM Tris pH8.0 containing 150mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS, 1mM PMSF, 2 /ml aprotinin, 2ug/ml leupeptin, 
50ug/ml soybean trypsin inhibitor, 10mM NaF, 1mM Na3VO4).  The mixture was then 
centrifuged at 12,000 rpm for 10 minutes in 4ºC.  The supernatant was then transferred to 
a new tube and the protein concentration was determined by Dc protein assay (Bio-Rad). 
For iNOS western blots, cells were lysed directly in 1% SDS (in 25 mM Tris-HCl, pH 
7.6,140 mM NaCl, and 5 mM EDTA), and boiled for 5 minutes. Equal amounts of total 
protein for each sample were resolved on SDS-PAGE gel and electo-transferred to a 
nitrocellulose membrane.  Nitrocellulose membranes were blocked in either 5% milk in 
T-BST or 1% BSA in TBS-T (20mM Tris-HCl, pH 7.4, 150mM NaCl, 0.1% Tween-20), 
and incubated with the appropriate antibodies.  The antibodies used were human 
prostasin ([24], used at 1:4,000), EGFR (sc-03, Santa Cruz Biotechnology, Santa Cruz, 
CA; 1:4,000), iNOS (610328), CD54/ICAM-1 (611704) and cyclin D1 (554181) (BD 
Biosciences, San Jose,CA; 1:800, 1:500 and 1:1,000), and β–tubulin (Sigma-Aldrich; 
1:4,000).After incubation with the appropriate primary antibody, the membranes were 
washed and incubated for one hour with the corresponding secondary antibody 
conjugated to the horseradish peroxidase (HRP) (1:10000).  The membranes were the 
washed and subjected to enhanced-chemiluminescence reaction (ECL, Pierce 
Biotechnology, Inc., Rockford, IL) before exposure to X-ray films.  
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RNA Isolation and Analysis by Reverse Transcription and Real-time Polymerase 
Chain Reaction: 
 
Cells were lysed with 500ul of TRIZOL Reagent (Invitrogen) and RNA was 
isolated according to manufacture’s protocol.  RNA concentrations were determined 
using spectrophotometry.   Reverse transcription was carried out using the iScript cDNA 
Synthesis Kit (Bio-Rad, Herules, CA).  Real-time PCR was carried out on a Bio-Rad 
MyiQ system using the iQ SYBR Green Supermix reagents (Bio-Rad).  PCR program 
and methods of quantification were described previsouly [18].  PCR primers’ sequences 
were designed with the aid of the Beacon Designer 4.0 software (PREMIER BioSoft 
International, Palo, Alto, CA) and synthesized by Integrated DAN Technologies 
(Coralville, IA).  The primers’ sequences are listed as below, in the order of forward and 
reverse: 
Β-Actin:  5’-TGG ACA TCC GCA AAG ACC TG-3’, 5’-CCG ATC CAC ACG GAG 
TAC TT-3’. 
Prostasin: 5’-ATC TTG GAT TAC TCC GGT CGG-3’, 5’-ACA CAT GGA CGC CTT 
CAT AGG-3’.   
Cyclin D1:  5’-GAC CTT CGT TGC CCT CTG-3’, 5’-AGG CGG TAG TAG GAC 
AGG-3’ 
iNOS:   5’-ATC TCT GGT CAA GCT GGA TGC-3’, 5’-GCC TTA TGG TGA AGT 
GTG TCT TG-3’ 
ICAM-1: 5’-ACA GTC ACC TAT GGC AAC-3’,5’-TGG CTT CGT CAG AAT CAC-3’ 
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Proliferation assay: 
  The siRNA-transfected BPH-1 cells were trypsinized and seeded in a 96-well 
plate at a density of 7.5 x 103 per well in triplicates for the CyQUANT® NF Cell 
Proliferation Assay using a kit (Invitrogen).  At 3 hours after seeding, cells were treated 
with the CyQUANT reagent for 30 minutes.  The fluorescence readout was measured 
using a Cary Eclipse Fluorescence Spectrophotometer (Varian, Inc., Walnut Creek, CA).  
This time point was designated as Day 0.  At 24, 48, and 72 hours after cell seeding, the 
procedures were repeated and the time points were designated as Day 1, Day 2, and Day 
3.   
  
Invasion assays: 
The procedures were modified from those described previously [15], using 
Transwell invasion chambers with 8-µm pore-size polycarbonate filters (Corning Inc., 
Lowell, MA).  The insert-filters were pre-coated with Matrigel (Sigma-Aldrich), at 50 
µg/20 µl per insert.  BPH-1 cells transfected with siRNA were trypsinized and seeded in 
the Transwell inserts at 1 x 105 cells per well.  The cells were allowed to invade for 24 
hours.  The inserts were then washed with cold 1x PBS twice and fixed with 4% 
paraformaldehyde for 30 minutes, washed again with 1x PBS and stained with 0.2% 
crystal violet.  The cells remaining on the top of the filters were removed with a cotton 
tip, and the cells on the underside of the filters were photographed.  The experiment was 
repeated three times. 
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 Statistical analysis: 
  Results of western blotting were digitally scanned and quantitatively analyzed by 
densitometry.  Data of western blotting were normalized with the value of β–tubulin.  
Gene expression evaluation using the quantitative real-time PCR data was performed by 
comparing the means of molecular equivalence of the target gene to the β-actin message.  
Statistical difference was evaluated by the Student t-Test (one-tailed, equal variance) and 
p < 0.05 was used to reject the null hypothesis. 
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RESULTS 
Prostasin expression in BPH tissue and the BPH-1 cell line  
We evaluated 12 pathologically confirmed BPH tissues for prostasin expression in 
the epithelial cells.  We have observed two distinct types of the glandular epithelial cells, 
a tall columnar-shaped and a flattened.  In Figure 1A, prostasin protein expression in the 
tall columnar-shaped glandular epithelial cells is shown, this staining pattern was 
observed in 11 out of the 12 tissues.  In the same view field, there are also areas with the 
same cell type but are negative for prostasin staining, which were observed in 10 out the 
12 tissues.  In Figure 1B, the basally located nuclei of the tall columnar-shaped glandular 
epithelial cells can be clearly seen, typical of the secretory luminal cells.  In Figures 1C 
and 1D, prostasin protein expression in the flattened glandular epithelial cells is shown, 
this staining pattern was observed in 11 out of the 12 tissues.  We have also identified 
areas of flattened glandular epithelial cells with negative prostasin staining in 9 out of the 
12 tissues (not shown).  Overall, in 8 out of the 12 tissues, we found all four different 
staining patterns, i.e., columnar/prostasin-plus, columnar/prostasin-minus, 
flattened/prostasin-plus, and flattened/prostasin-minus.  It is unclear what the two distinct 
types of glandular epithelial cells represent in terms of BPH pathology or cell biology. 
However, it is important to point out that some of the areas of tissue were negative, 
meaning they are not ‘normal’.  An absolutely normal prostate would have 100% of the 
epithelial cells stained for prostasin.  
 Prostasin is also expressed in the BPH-1 cell line, as shown by the western blot 
results in Fig. 2. We then sought to investigate prostasin’s functional role in BPH by 
down-regulating its expression in the BPH-1 cell line. In Fig. 2, we show the effect of a 
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prostasin-specific siRNA (Pro-siRNA) transfected in the BPH-1 cells on prostasin 
proteinexpression, which was reduced by 55% (p < 0.05, densitometry data not shown), 
when 11 compared to the untreated cells (Parent), or cells treated with a randomized 
controlsiRNA (Con-siRNA) or Lipofectamine 2000 alone (Lipids). The prostasin mRNA 
expression in the Pro-siRNA treated cells was also reduced, by 68% when compared to 
the untreated Parent cells (Table I). The liposomes or the control siRNA did not have an 
effect on prostasin mRNA (Table I) or protein expression (Fig. 2, p > 0.05, among the 
controls). 
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 Figure 1  Expression of prostasin protein in BPH.  BPH tissues were subjected to 
immunohistochemistry analysis.  Prostasin-positive staining is shown by the brown color.  
A. A representative area of glandular BPH with tall columnar-shaped epithelial cells 
stained for prostasin expression.  This area also shows the same cell type negative for 
prostasin expression.  Image was taken with a 10x objective lens and a 0.45x coupler to a 
SONY DXC-950 3CCD camera.  B. A high-magnification view of the boxed area in A 
(40x objective lens).  C. A representative area of glandular BPH with the flattened 
epithelial cells stained for prostasin expression.  Magnification: same as in A.  D. A high-
magnification view of the boxed area in C (40x objective lens).
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Table 1.  Analysis of Immunohistochemisty  
 
BPH IHC for 
Prss8 Columnar    Flat   
Slide Numbers Positive Negative Positive Negative
1 X X X X 
2 X X X X 
3 NE NE  X X 
4 X X X X 
5 X X X X 
6 X X X X 
7 X NE NE NE  
8 X X X X 
9 X X X NE 
10 X X X X 
11 X X X NE 
12 X X X X 
  11/12 10/12 11/12 9/12 
 
 
 15
Prostasin Silencing in BPH-1 Cells Increased iNOS and ICAM-1 Expression 
 
Prostasin expression is repressed during inflammation while a forced prostasin 
expression could attenuate inflammatory gene expression response, specifically, that of 
the inducible nitric oxide synthase (iNOS) [19,23]. We analyzed the prostasin-silenced 
BPH-1 cells (Pro-siRNA) for changes of iNOS expression, and found that at the mRNA 
level, there was an induction of iNOS expression to > 13 fold when compared to the 
untreated parent cells (Table I). The liposomes or the control siRNA did not have an 
effect on iNOS mRNA expression. At the protein level, only the prostasin-silenced 
BPH-1 cells were shown to express a detectable amount of iNOS (Fig. 2). 
In the classic human prostate cancer cell lines, two that do not express prostasin 
(DU-145 and PC-3) [15] expressed a high level of intercellular adhesion molecule-1 
(ICAM-1) [26], while one with prostasin expression (LNCaP) [15] did not express 
ICAM-1 [26]. ICAM-1 expression in the DU-145 and PC-3 cells responded to cytokine 
stimulation [27], conditions reminiscent of inflammation, which represses prostasin 
expression. We asked if prostasin silencing in the BPH-1 cells could affect ICAM-1 
expression because prostasin was proposed to regulate cytokine-induced inflammatory 
gene expression [23]. An induction of ICAM-1 expression to 2.47 fold at the mRNA 
level (Table I), and to ~2.7 fold at the protein level (Fig. 2, p < 0.05, versus the controls), 
was observed in the prostasin-silenced BPH-1 cells, when compared to the untreated 
cells. The liposomes or the control siRNA did not have an effect on ICAM-1 mRNA 
(Table I) or protein expression (Fig. 2, p > 0.05, among the controls). 
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Prostasin silencing in BPH-1 cells down-regulated cyclin D1 
Prostasin has recently been shown to modulate EGFR-mediated cell signaling in 
prostate cancer cells by protease-dependent and protease-independent mechanisms 
[19,20].  EGFR-mediated cell signaling regulates cyclin D1 expression and cellular 
responses mediated by cyclin D1 in the prostate [26].  We have observed both prostasin-
positive and prostasin-negative glandular epithelial cells in the clinical BPH tissues, and 
we sought to investigate prostasin’s functional role in this context by down-regulating its 
expression in the BPH-1 cell line.  In Figure 2, we show the effect of a prostasin-specific 
siRNA (Pro-siRNA) transfected in the BPH-1 cells on prostasin protein expression, 
which was reduced by > 50% (p < 0.05, densitometry data not shown), when compared to 
the untreated cells (Parent), or cells treated with a randomized siRNA (Con-siRNA) or 
lipids alone (Lipids).  The prostasin protein expression levels were not different among 
the three control cell types (p > 0.05).  The prostasin mRNA expression in the Pro-siRNA 
treated cells was also reduced by > 50% (p < 0.05) when compared to the control cells.  
The protein expression of cyclin D1 of the Pro-siRNA treated BPH-1 cells was reduced 
by > 50% as determined by the western blots (p < 0.05, versus the controls).  The three 
control cell types were shown to express similar levels of cyclin D1 (p > 0.05).  The 
cyclin D1 down-regulation associated with prostasin silencing is at the transcriptional 
levels as the cyclin D1 mRNA in the Pro-siRNA treated cells was down-regulated by      
> 50% as well (p < 0.05, versus the controls).  For prostasin as an extracellular serine 
protease to regulate cyclin D1 expression at the transcriptional level, a transmembrane 
molecular mechanism must serve as a relay for the signal.  We examined the protein 
expression of EGFR, a putative prostasin substrate and a regulator of cyclin D1 
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expression.  EGFR protein expression, however, was not affected in association with 
prostasin silencing in the BPH-1 cells, as shown in Figure 2.  Prostasin modulation of 
EGFR-mediated signaling is accompanied by EGFR cleavage in the extracellular domain 
[20], or changes of EGFR protein expression [19].  In the BPH-1 cells, we did not 
observe these trademarks for the previously known mechanisms of EGFR signal 
modulation by prostasin.   A novel molecular mechanism, different from that mediated by 
EGFR, must be suggested for prostasin’s regulatory role in cyclin D1 expression. 
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Fig. 2. Prostasin silencing in BPH-1 cells resulted in protein expression changes 
of iNOS, ICAM-1, and cyclin D1. Images are representative of three independent 
western blotting experiments. Samples loaded in the gels are indicated in the figure: 
Parent, untreated BPH-1 cells; Pro-siRNA, cells transfected with a prostasin-specific 
siRNA; Con-siRNA, cells transfected with a randomized control siRNA; Lipids, cells 
treated with Lipofectamine 2000 alone. For the Prostasin blots, 10 μg of total protein 
per sample were analyzed by non-reducing SDS-PAGE. For the iNOS blots, 40 μg of 
total protein per sample were analyzed by reducing SDS-PAGE. For the ICAM-1, 
Cyclin D1, EGFR, and β-Tubulin blots, 45 μg of total protein per sample were analyzed 
by reducing SDS-PAGE. 
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Prostasin silencing in BPH-1 cells decreased cell proliferation 
It has recently been shown that over-expression of cyclin D1 in the BPH-1 cell 
line resulted in increased cell proliferation in vitro, and in larger as well as more 
vascularized grafts when recombined with rat urogenital mesenchyme (rUGM) under the 
kidney capsule of severe combined immunodeficient (SCID) mice [25].  We asked if the 
cyclin D1 down-regulation associated with prostasin silencing in the BPH-1 cells would 
have an impact on cell proliferation.  In Figure 3, we show that the Pro-siRNA treated 
cells were proliferating at a rate which was only at ~ 60% of the cells treated with Con-
siRNA or Lipids on Day 3 (p < 0.05).  The cells treated with Con-siRNA or Lipids were 
also proliferating at lower rates (~ 74% on Day 3) than the untreated BPH-1 (Parent) cells 
(p < 0.05).  We attribute the reduced proliferation rates of the Con-siRNA or Lipids 
treated cells to the effects of the liposomes as all cell types except the parent were treated 
with an equal amount of liposomes.  It has been reported previously that liposomes alone 
could produce growth inhibitory effects on cultured cells [27].  The liposome-induced 
growth suppression did not mask the effect of prostasin silencing on proliferation because 
the proliferation rate of the Pro-siRNA treated cells was lower than that of the cells 
treated with either the Con-siRNA or Lipids.  The liposomes, however, did not have a 
repressive effect on prostasin expression (Figure 2).  The growth inhibition effect 
secondary to prostasin silencing is hereby viewed to be independent of the liposomes’ 
effects and specific to the prostasin-silencing event. 
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Figure 3 Prostasin silencing in BPH-1 cells decreased cell proliferation.  The 
siRNA-transfected BPH-1 cells were subjected to the CyQUANT® NF Cell Proliferation 
Assay along with the controls, as indicated in the figure.  At times indicated, the 
fluorescence was measured as a surrogate of cell density.  The data were expressed as t
relative increases from the first point (Day 0), and were from three independent 
experiments.   
he 
 23
 Prostasin silencing in BPH-1 cells decreased cell invasion through Matrigel 
Over-expression of cyclin D1 in the BPH-1 cells also induced cell migration 
changes that resulted in increased invasion through Matrigel [15].  We asked if the cyclin 
D1 down-regulation associated with prostasin silencing in the BPH-1 cells would impact 
invasion.  In Figure 4, we show that the Pro-siRNA treated BPH-1 cells were no longer 
invading through the Matrigel.  We performed the experiments as described by He et al. 
[25], using exactly the same amount of Matrigel coating and the same number of starting 
cells (100,000), except that we had allowed the invasion to proceed for twice as long (24 
hours versus 12 hours).  Even under the prolonged invasion, Pro-siRNA treated BPH-1 
cells were not invasive.  The data presented in Figure 4 are therefore, qualitative but not 
quantitative because the Pro-siRNA treated cells had hardly any invasion.  The 
ifferences of invasion we had observed between the Pro-siRNA treated cells and the 
lls w
feration 
re 
ference was observed for the differently treated cells (data not shown).  
The reduced invasion of the Pro-siRNA treated BPH-1 cells is most likely a change of 
migratory potential, which can be directly regulated by cyclin D1 [25].  Once again, the 
liposomes produced an inhibitory effect on cell invasion as cells treated with the Con-
siRNA or Lipids were equally less invasive than the untreated (Parent) cells.  Cationic 
d
control ce ere not the result of a differential proliferation rate, because at the time 
point of stopping the invasion assays (i.e., 24 hours, equivalent to Day 1 in the 
proliferation assays), the differently treated cells did not show a measurable proli
rate difference.  We evaluated the proteolytic profiles of matrix metalloproteases (MMP-
2 and MMP-9) by gelatin zymography assays of the secreted MMP’s in the cultu
medium, no dif
 24
liposom acids into cultured cells, such as the 
nhibit 
tumor c
 
es used for transfecting nucleic 
Lipofectamine 2000 reagent used in this study, were also shown previously to i
ell metastatic capabilities [28].  But the Pro-siRNA treated cells were non-
invasive, clearly different from the cells treated with the Con-siRNA or Lipids.  The 
invasion inhibition effect secondary to prostasin silencing is also viewed to be 
independent of the liposomes’ effects and specific to the prostasin-silencing event. 
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Figure 4 Prostasin silencing in BPH-1 cells decreased cell invasion through 
Matrigel.  The siRNA-transfected BPH-1 cells were subjected to Matrigel invasion 
assays along with the controls, as indicated in the figure.  Images shown were 
representative of three independent experiments
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DISCUSSION 
In this study, we have demonstrated prostasin expression in the glandular 
epithelial cells in prostate tissues presenting clinical BPH, and at the same time shown 
areas where the glandular epithelial cells are negative for prostasin expression. At 
present, the pathological and molecular mechanisms for this differential expression of 
prostasin in BPH tissues are not known. As the majority of the tissues examined (8/12) 
presented both cell types with positive and negative prostasin staining, the differential 
expression of prostasin in the BPH glands does not seem related to systemic factors but 
instead may be indicative of what goes on in the prostate microenvironment. For 
example, the expression pattern may be determined by whether a particular region of the 
tissue was more exposed to prostasin expression regulatory factors, such as inflammation. 
We had previously shown that inflammation is a prostasin expression silencing event in 
the mouse bladder [23], and induction of SLUG expression by androgen could also 
re asin r 
exp
studie he 
BPH tissues.   
One of the cellular responses to inflammation, specifically the actions of the 
inflammatory cytokines, is the production of nitric oxide (NO.) by the inducible nitric 
oxide synthase (iNOS), a mechanism also active in the epithelial cells [29]. NO.  is highly 
relevant to BPH and treatment of BPH. The roles of NO. and of the constitutively 
expressed nitric oxide synthases (neuronal/nNOS/NOS1 and endothelial/eNOS/NOS3) 
press prost expression in the prostate [15]. It is also possible that androgen recepto
ression states of the BPH tissues might affect prostasin expression as well. Future 
s are needed to address the mechanisms of differential prostasin expression in t
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in the major clinical symptoms of BP  and erectile dysfunction (ED), 
have be mptoms 
 
te 
H 
e 
w- 
r 
 high-grade PIN and cancer showing higher intensities than BPH and 
low-gra l 
 the 
tissues studied, but at least we confirm the capability of prostate epithelial cells to express 
H, namely LUTS
en extensively studied [30,31]. Drugs aimed at improving clinical BPH sy
have been shown to involve NO.-related mechanisms [32-36], but mostly concern the 
nerve tissues and other non-prostate tissues. The prostate epithelial cells were 
reported to express both nNOS (secretory cells) and eNOS (basal cells) [37]. iNOS has
been shown by one study to be expressed in all BPH tissues (n = 10, with or without 
prostatitis) at the mRNA and the protein levels, while not detected in the normal prosta
tissues [37]. The iNOS was localized to the smooth muscle and fibroblast cells in this 
study [37]. In another study, iNOS mRNA was found to be down-regulated in BP
samples (n = 9) at the mRNA level versus the normal tissues (n = 12), using RNA 
extracted from frozen tissue sections [38]. No localization information was available 
from the second study, but the average epithelial contents of the specimens were 
provided. The BPH tissues had an epithelial content of 56% (range of 40-70%) whil
the normal tissues’ was at 69% (55-85%) [33]. Yet a third study reported epithelial-
localized iNOS immunoreactivity or expression in samples from patients with BPH, lo
or high-grade prostatic intraepithelial neoplasia (PIN), and prostate carcinoma (n = 20 fo
each type), with
de PIN [39]. The prostate epithelial-localized iNOS was seen in both the basa
and the secretory cell types [39]. We have shown that the BPH-1 cells, which were 
characterized to be the secretory epithelial type [21], are capable of an induced iNOS 
expression with the inducing event being prostasin silencing. The heterogeneity of
reported iNOS expression in BPH probably also reflects the heterogeneity of the BPH 
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iNOS in response to prostasin expression changes in vitro, suggesting a potential 
functional role for both prostasin and iNOS in benign prostate diseases. 
Along with iNOS, the expression of ICAM-1 was also induced in association with 
e signal 
 
ing 
ed 
 
MB-
 in 
prostasin silencing. We have previously proposed a protease-dependent cytokin
modulating role for prostasin to regulate inflammatory gene expression [123].  ICAM-1 
is a cytokine-regulated gene in cells of the prostate epithelial origin [40], and its 
expression change in the BPH-1 cells was consistent with this proposed role for prostasin.
As opposed to the up-regulation of iNOS and ICAM-1 associated with prostasin silenc
in the BPH-1 cells, the expression of cyclin D1 was down-regulated.  To explore a 
potential mechanism for the cyclin D1 down-regulation, we examined the protein 
expression of EGFR. Prostasin modulation of EGFR-mediated signaling is accompani
by EGFR cleavage in the extracellular domain [20], or changes of EGFR protein 
expression [19]. In the BPH-1 cells, we did not observe these trademarks for the 
previously known mechanisms of EGFR signal modulation by prostasin. A novel 
molecular mechanism, different from that mediated by EGFR, must be suggested for 
prostasin’s regulatory role in cyclin D1 expression.  
The increased iNOS expression at the protein level in prostasin-silenced BPH-1
cells, with the expected boost of NO production could be a mechanism for cyclin D1 
down-regulation, as previously reported for the human breast cancer cell line MDA-
231 using the NO. donor DETA-NONOate (1 mM) [41].  There was no notable change
CDK4, CDK6, CDK2, cyclin D2, cyclin D3, or cyclin E [41].  It is shown that this 
decrease of cyclin D1 is due to a decrease in cyclin D1 synthesis and not due to its 
degradation [41].  This is evidenced by the fact that a decrease in cyclin D1 protein 
 29
preceded the decrease in cyclin D1 mRNA.  It was also shown the the NO. donor h
effect on the half-life of cyclin D1 in this breast cancer cell line, therefor
ad no 
e ruling out 
degrada
ively 
he 
 [15]. 
to 
e 
le, 
ty via cytoskeleton remodeling and 
membr
g that 
tion [41].  NO. must be regulating cyclin D1 at the translational or 
posttranslational stage [41].  They also ruled out the possibility of cGMP mediating the 
effects of NO. on cyclin D1 [41].  The cell cycle regulatory protein cyclin D1 is 
expressed at normal levels in clinical BPH tissues [42], and is positively or negat
responsive to transcriptional regulation in the BPH-1 cell line [43]. It was not unexpected 
that the cyclin D1 down-regulation is accompanied by a growth inhibition effect on the 
BPH-1 cells because of cyclin D1’s established role in cell cycle regulation, and in t
BPH-1 cells [25]. It was unexpected, however, that an event involving prostasin 
expression change resulted in changes of cell proliferation because we had previously 
shown that re-expression of prostasin in cancer cell lines did not affect cell growth
One could speculate that the cancer cells no longer possess the cellular pathways 
respond properly to prostasin on cell proliferation signals, whereas the pathways ar
intact in the BPH-1 cells to allow this readout. In addition to its cell cycle regulation ro
cyclin D1 has also been shown to regulate cell motili
ane ruffling [44], while over-expression of cyclin D1 in the BPH-1 cells did also 
result in increased invasion via increased cell motility [15]. The cyclin D1 down-
regulation in the prostasin-silenced BPH-1 cells, along with the increased expression of 
iNOS and ICAM-1 may be responsible for the phenotypic change to almost completely 
non-invasive. But this finding seemed to contradict our previous observations that 
prostasin acted as an invasion suppressor in cancer cells [15]. Again, the new findin
prostasin silencing in the BPH-1 cells actually reduced, instead of increasing cell 
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invasiveness or motility may be the result of different molecular mechanisms at play. We
evaluated the proteolytic profiles of matrix metalloproteases (MMP-2 and MMP-9) b
gelatin zymography assays of the secreted MMP’s in the culture medium, n
was observed for the differently treated cells (data not shown). The reduced invasion of 
the Pro-siRNA treated BPH-1 cells is most likely a change of migratory potentia
can be directly regulated by cyclin D1 [25], iNOS [45], and ICAM-1 [46]. 
 
 
 
y 
o difference 
l, which 
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